TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07723833: A Phase I, Randomized, Single-dose, Crossover, 2-Period, Open-Label Study to Assess the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

Sponsor: AstraZeneca · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 152 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07723833 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07723833 Rescue Dossier →